Accessibility Menu
Aft Pharmaceuticals logo

Aft Pharmaceuticals

(ASX) AFP

Current PriceA$3.07
Market CapA$321.94M
Since IPO (2016)+6%
5 Year-25%
1 Year+24%
1 Month-3%

Aft Pharmaceuticals Financials at a Glance

Market Cap

A$321.94M

Revenue (TTM)

NZ$462.82M

Net Income (TTM)

NZ$26.75M

EPS (TTM)

A$0.12

P/E Ratio

25.02

Dividend

A$0.02

Beta (Volatility)

0.05 (Low)

Price

A$3.07

Volume

2,375

Open

A$3.20

Previous Close

A$3.07

Daily Range

A$3.07 - A$3.20

52-Week Range

A$2.20 - A$3.37

Estimated Earnings Date

Nov 19, 2026

AFP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aft Pharmaceuticals

Industry

Pharmaceuticals

Employees

126

CEO

Hartley Atkinson, PhD

Headquarters

Auckland, 0622, NZ

AFP Financials

Key Financial Metrics (TTM)

Gross Margin

43%

Operating Margin

10%

Net Income Margin

6%

Return on Equity

14%

Return on Capital

16%

Return on Assets

7%

Earnings Yield

4.00%

Dividend Yield

0.54%

Payout Ratio

12.81%

Stock Overview

Market Cap

A$321.94M

Shares Outstanding

104.87M

Volume

2.38K

Avg. Volume

1.82K

Financials (TTM)

Gross Profit

NZ$111.36M

Operating Income

NZ$25.04M

EBITDA

NZ$28.76M

Operating Cash Flow

-NZ$11.84M

Capital Expenditure

-NZ$116.84K

Free Cash Flow

-NZ$11.95M

Cash & ST Invst.

NZ$10.31M

Total Debt

NZ$54.50M

Aft Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

NZ$140.78M

+25.9%

Gross Profit

NZ$61.30M

+17.1%

Gross Margin

43.55%

N/A

Market Cap

A$321.94M

N/A

Market Cap/Employee

A$2.93M

N/A

Employees

110

N/A

Net Income

NZ$11.52M

-16.5%

EBITDA

NZ$21.52M

+3.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

NZ$10.31M

-14.3%

Total Debt

NZ$54.50M

+69.3%

Accounts Receivable

NZ$64.70M

+57.8%

Inventory

NZ$74.61M

+52.1%

Long Term Debt

NZ$41.90M

+33.5%

Short Term Debt

NZ$12.60M

+1483.4%

Return on Assets

6.79%

N/A

Return on Invested Capital

16.50%

N/A

Free Cash Flow

-NZ$11.27M

-152.8%

Operating Cash Flow

-NZ$11.22M

-152.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTX.AXTetratherix Ltd.
A$6.00+14.29%
MVF.AXMonash IVF Group Limited
A$0.69+2.24%
ARX.AXAroa Biosurgery Limited
A$0.65+5.69%
IMR.AXImricor Medical Systems, Inc.
A$1.75+4.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%
SMCISuper Micro Computer
$30.46-0.05%

Questions About AFP

What is the current price of Aft Pharmaceuticals?

Aft Pharmaceuticals is trading at A$3.07 per share.

What is the 52-week range for Aft Pharmaceuticals?

Over the past 52 weeks, Aft Pharmaceuticals has traded between A$2.20 and A$3.37.

How much debt does Aft Pharmaceuticals have?

As of the most recent reporting period, Aft Pharmaceuticals reported total debt of NZ$45.07M.

How much cash does Aft Pharmaceuticals have on hand?

Aft Pharmaceuticals reported NZ$8.53M in cash and cash equivalents in its most recent financial results.

What is Aft Pharmaceuticals’s dividend yield?

Aft Pharmaceuticals currently has a dividend yield of 0.54%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.